Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (111 ops.)
Latest filing published 13 Jan 2026 for Madrigal Pharmaceuticals, INC., €883k.
Filing timeline
BuySalePaul A. Friedman
Insider track record
Disclosed buys
2
Disclosed sells
111
Signal history
Closed purchases
Market purchases
2
Positive at T+90
100%
Median T+90
+10.8%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -12.6%Entry US$121.92 · Close at T+365 US$106.53
- -13.4%Entry US$114.00 · Close at T+365 US$98.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Paul A. Friedman: trading record in brief
Paul A. Friedman appears as a Director at five companies, according to 154 filings published from July 26, 2016 to January 13, 2026. Madrigal Pharmaceuticals, Inc. holds 128 of them, ahead of Incyte Corp (14), Alexion Pharmaceuticals Inc (7), Cerulean Pharma Inc. (3) and Prelude Therapeutics Inc (2).
The 111 sales come to EUR 150,209,996, with a median of EUR 639,523. The largest, EUR 17,951,044, is dated June 11, 2018. Two others, EUR 9,212,389 and EUR 7,702,944, are from August 13, 2025. The two purchases, on November 19, 2018 and November 20, 2018, are EUR 434,556 and EUR 411,628, both at Madrigal Pharmaceuticals, Inc. There are also 19 grants, 19 option exercises and 3 filings of another kind.
The calendar tightens toward the end: 33 filings in 2024, 56 in 2025 and 31 in 2026, against 3 to 11 a year from 2016 to 2021 and a single one in 2023. The last twelve months hold 41 filings, 38 of them sales.
At Madrigal Pharmaceuticals, Inc., 105 of Friedman's trades are close to trades by Rebecca Taub, 67 to trades by William John Sibold, 66 to trades by Kenneth Bate and 58 to trades by Shannon T. Kelley, in the same direction.
Companies and markets linked to Paul A. Friedman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations154 total
1,996 shares@ US$515.810.7% of flowCommon StockSEC:0001628280-26-001976:4
766 shares@ US$516.840.3% of flowCommon StockSEC:0001628280-26-001976:5
2,450 shares@ US$517.860.8% of flowCommon StockSEC:0001628280-26-001976:6
1,363 shares@ US$518.680.5% of flowCommon StockSEC:0001628280-26-001976:7
846 shares@ US$519.880.3% of flowCommon StockSEC:0001628280-26-001976:8
280 shares@ US$551.240.1% of flowCommon StockSEC:0001628280-26-001981:1
1,480 shares@ US$511.980.5% of flowCommon StockSEC:0001628280-26-001976:1
1,094 shares@ US$513.110.4% of flowCommon StockSEC:0001628280-26-001976:2
1,345 shares@ US$514.680.5% of flowCommon StockSEC:0001628280-26-001976:3
681 shares@ US$521.030.2% of flowCommon StockSEC:0001628280-26-001976:9
840 shares@ US$521.980.3% of flowCommon StockSEC:0001628280-26-001976:10
970 shares@ US$523.000.3% of flowCommon StockSEC:0001628280-26-001976:11
1,199 shares@ US$524.100.4% of flowCommon StockSEC:0001628280-26-001976:12
2,432 shares@ US$525.050.8% of flowCommon StockSEC:0001628280-26-001976:13
1,066 shares@ US$526.000.4% of flowCommon StockSEC:0001628280-26-001976:14
1,560 shares@ US$526.970.5% of flowCommon StockSEC:0001628280-26-001976:15
575 shares@ US$528.180.2% of flowCommon StockSEC:0001628280-26-001976:16
691 shares@ US$529.170.2% of flowCommon StockSEC:0001628280-26-001976:17
166 shares@ US$529.760.1% of flowCommon StockSEC:0001628280-26-001976:18
280 shares@ US$530.690.1% of flowCommon StockSEC:0001628280-26-001976:19
80 shares@ US$532.500.0% of flowCommon StockSEC:0001628280-26-001976:20
332 shares@ US$534.160.1% of flowCommon StockSEC:0001628280-26-001976:21
148 shares@ US$535.290.1% of flowCommon StockSEC:0001628280-26-001976:22
473 shares@ US$536.020.2% of flowCommon StockSEC:0001628280-26-001976:23
487 shares@ US$536.880.2% of flowCommon StockSEC:0001628280-26-001976:24
25 of 154 declarations
